Article Text

Download PDFPDF
Hepatitis A, hepatitis B and HPV vaccine needs and coverage in MSM initiating HIV PrEP in a sexual health clinic in Paris
  1. Vincent Bérot1,
  2. Anton Eremin1,
  3. Antoine Fauchois1,
  4. Jeanne Dechamp1,
  5. Luminita Schneider1,
  6. Aziza Chermak1,
  7. Antoine Faycal1,
  8. Baptiste Sellem1,
  9. Thibault Orriere1,
  10. Marion Favier1,
  11. Roland Tubiana1,2,
  12. Marc-Antoine Valantin1,2,
  13. Valerie Pourcher1,2,
  14. Eve Todesco2,3,
  15. Gentiane Monsel1,
  16. Rachid Agher1,
  17. Romain Palich1,2,
  18. Christine Katlama1,2
  1. 1Sorbonne University, Infectious Diseases Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, Île-de-France, France
  2. 2INSERM U1136, Pierre Louis Epidemiology and Public Health Research Institute, Paris, Île-de-France, France
  3. 3Sorbonne University, Virology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, Île-de-France, France
  1. Correspondence to Christine Katlama, Sorbonne University, Infectious Diseases Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France; christine.katlama{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


Pre-exposure prophylaxis (PrEP) with tenofovir disoproxil/emtricitabine is a powerful tool to prevent HIV acquisition and provides an opportunity to offer comprehensive prevention services, including assessment for sexually transmitted infections and evaluation of immune status towards vaccine-preventable viral infections such those due hepatitis A virus (HAV), hepatitis B virus (HBV) and human papillomavirus (HPV). In addition to the programme in girls aged 11–19, French guidelines recommended HPV vaccination for men who have sex with men (MSM) ≤26 years old in February 20161 and for all boys aged 11–19 in December 2019.2 There are no restrictions on HPV vaccine use beyond these age limits, but the cost is not covered by the French Health Service. In real-life settings, suboptimal vaccination coverage against HPV as well as HBV has been reported among European MSM.3 4

Our objective was to evaluate HAV, HBV and HPV vaccine needs and coverage in individuals initiating PrEP in a sexual health clinic in Paris. In this observational retrospective single-centre study, we reviewed all individuals who initiated PrEP between 1 January 2016 and 31 December 2020 with ≥1 year of follow-up after PrEP initiation. At baseline, we assessed the presence of HAV and HBV antibodies and HPV vaccination status. Immune …

View Full Text


  • Handling editor Anna Maria Geretti

  • Contributors VB, RP, JD and CK contributed to the study design and developing analysis plan. AFau, JD, RA, CK, VB and AE contributed to the analysis and interpretation of data. VB and AE wrote the first draft of the manuscript and subsequent drafts after revisions. CK reviewed all versions of the manuscript. VB, AE, AFau, JD, LS, AC, AFay, BS, TO, MF, RT, M-AV, VP, ET, GM, RP and CK contributed to the recruitment of participants, reviewed the final version of the manuscript and contributed to the interpretation of the data.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.